PMC:7195088 / 29725-31117
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T29 | 79-87 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T30 | 240-248 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T31 | 436-440 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
| T32 | 1215-1217 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T33 | 1231-1239 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T23 | 436-440 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T28 | 79-93 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T29 | 136-145 | Phenotype | denotes | pneumonia | http://purl.obolibrary.org/obo/HP_0002090 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T151 | 54-62 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T152 | 88-102 | Disease | denotes | storm syndrome | http://purl.obolibrary.org/obo/MONDO_0008496 |
| T153 | 136-145 | Disease | denotes | pneumonia | http://purl.obolibrary.org/obo/MONDO_0005249 |
| T154 | 147-151 | Disease | denotes | ARDS | http://purl.obolibrary.org/obo/MONDO_0006502 |
| T155 | 353-361 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T156 | 441-447 | Disease | denotes | injury | http://purl.obolibrary.org/obo/MONDO_0021178 |
| T157 | 545-553 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T158 | 845-853 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T159 | 1048-1056 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T160 | 1281-1289 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T162 | 19-20 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T163 | 77-78 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T164 | 368-373 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T165 | 436-440 | http://purl.obolibrary.org/obo/UBERON_0002048 | denotes | lung |
| T166 | 436-440 | http://www.ebi.ac.uk/efo/EFO_0000934 | denotes | lung |
| T167 | 560-565 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T168 | 1063-1068 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
| T169 | 1120-1121 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T170 | 1154-1155 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T171 | 1296-1301 | http://purl.obolibrary.org/obo/CLO_0007225 | denotes | label |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T398 | 183-198 | Chemical | denotes | corticosteroids | http://purl.obolibrary.org/obo/CHEBI_50858 |
| T399 | 289-307 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T400 | 368-373 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T401 | 488-506 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T402 | 560-565 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T403 | 678-683 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
| T404 | 684-694 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T405 | 700-718 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T406 | 724-734 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T407 | 739-750 | Chemical | denotes | thalidomide | http://purl.obolibrary.org/obo/CHEBI_9513 |
| T408 | 764-769 | Chemical | denotes | alpha | http://purl.obolibrary.org/obo/CHEBI_30216 |
| T409 | 770-780 | Chemical | denotes | interferon | http://purl.obolibrary.org/obo/CHEBI_52999 |
| T410 | 786-804 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T411 | 810-820 | Chemical | denotes | umifenovir | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T412 | 1012-1030 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T413 | 1063-1068 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
| T414 | 1215-1217 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T416 | 1245-1263 | Chemical | denotes | methylprednisolone | http://purl.obolibrary.org/obo/CHEBI_6888 |
| T417 | 1296-1301 | Chemical | denotes | label | http://purl.obolibrary.org/obo/CHEBI_35209 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T229 | 0-362 | Sentence | denotes | Methylprednisolone A subgroup of patients with severe COVID-19 might develop a cytokine storm syndrome which causes rapidly progressive pneumonia, ARDS and clinical deterioration and corticosteroids administration may halt the dysregulated cytokine release • Not available • Comparison of methylprednisolone vs. standard of care in patients with severe COVID-19. |
| T230 | 363-404 | Sentence | denotes | Open-label RCT (NCT04244591, recruiting). |
| T231 | 405-471 | Sentence | denotes | Primary endpoint: lower Murray lung injury score at days 7 and 14. |
| T232 | 472-554 | Sentence | denotes | • Comparison of methylprednisolone vs. standard of care in patients with COVID-19. |
| T233 | 555-596 | Sentence | denotes | Open-label RCT (NCT04273321, recruiting). |
| T234 | 597-653 | Sentence | denotes | Primary endpoint: treatment failure (follow-up 14 days). |
| T235 | 654-854 | Sentence | denotes | • Comparison of inhaled alpha interferon plus methylprednisolone plus umifenovir vs. thalidomide plus inhaled alpha interferon plus methylprednisolone plus umifenovir in patients with severe COVID-19. |
| T236 | 855-906 | Sentence | denotes | Double-blind RCT (NCT04273581, not yet recruiting). |
| T237 | 907-974 | Sentence | denotes | Primary endpoint: time to clinical improvement (follow-up 28 days). |
| T238 | 975-1057 | Sentence | denotes | • Comparison of different dosages of methylprednisolone in patients with COVID-19. |
| T239 | 1058-1099 | Sentence | denotes | Open-label RCT (NCT04263402, recruiting). |
| T240 | 1100-1181 | Sentence | denotes | Primary endpoints: (a) disease readmission at day 7; (b) critical stage at day 7. |
| T241 | 1182-1290 | Sentence | denotes | • Comparison of siltuximab (anti–IL-6 monoclonal antibody) vs. methylprednisolone in patients with COVID-19. |
| T242 | 1291-1340 | Sentence | denotes | Open-label RCT (NCT04329650, not yet recruiting). |
| T243 | 1341-1392 | Sentence | denotes | Primary endpoint: ICU admission (follow-up 29 days) |